Cavity Margin Status Is an Independent Risk Factor for Local-Regional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Before Breast-Conserving Surgery
Available accessResearch articleFirst published online December, 2011
Cavity Margin Status Is an Independent Risk Factor for Local-Regional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Before Breast-Conserving Surgery
The objection of this study is to investigate whether the cavity margin (CM) status has different predictive efficacy for local-regional recurrence (LRR) in patients who have received or have not received neoadjuvant chemotherapy (NAC) before breast-conserving surgery. We identified 61 patients who received NAC before breast-conserving surgery. A nonrandomized unmatched cohort of 295 patients without history of receiving NAC were also included in this study. Clinicopathological features and follow-up data were abstracted and analyzed. Patients in the NAC-treated group had more advanced diseases when compared with patients in the non NAC-treated group. With a median follow-up of 42 months, the LRR-free survival rate of patients with positive CMs was significantly lower than that of patients with negative CMs in the NAC-treated group. This distinction was not observed in the nonNAC-treated group. Univariate and multivariate analysis revealed that positive CM was the only independent predictive factor for LRR in the NAC-treated group but not in nonNAC-treated patients. CM status had different predictive efficacy for LRR in different settings. Association between CM status and LRR was observed in NAC-treated patients rather than nonNAC-treated patients. More extensive surgical treatment might be needed in NAC-treated patients when their CMs are positive.
References
1.
MauriD., PavlidisN., IoannidisJ.P.Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.J Natl Cancer Inst2005; 97: 188–94.
GentiliniO., IntraM., GandiniS.Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome.J Surg Oncol2006; 94: 375–9.
4.
ChenA.M., Meric-BernstamF., HuntK.K.Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.J Clin Oncol2004; 22: 2303–12.
5.
SanghaniM., BalkE., CadyB., WazerD.Predicting the risk of local recurrence in patients with breast cancer - An approach to a new computer-based predictive tool.American Journal of Clinical Oncology-Cancer Clinical Trials2007; 30: 473–80.
6.
SingletaryS.E.Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy.Am J Surg2002; 184: 383–93.
7.
FisherE.R., SassR., FisherB.Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). II. Relation of local breast recurrence to multicentricity.Cancer1986; 57: 1717–24.
8.
HewesJ.C., ImkampeA., HajiA., BatesT.Importance of routine cavity sampling in breast conservation surgery.Br J Surg2009; 96: 47–53.
9.
PovoskiS.P., JimenezR.E., WangW.P., XuR.X.Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer.BMC Cancer2009; 9: 254.
10.
VeronesiU., BonadonnaG., ZurridaS.Conservation surgery after primary chemotherapy in large carcinomas of the breast.Ann Surg1995; 222: 612–8.
11.
NakamuraS., KenjoH., NishioT.Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy.Breast Cancer2002; 9: 15–9.
12.
Akashi-TanakaS., FukutomiT., SatoN.The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery.Ann Surg2004; 239: 238–43.
13.
SchwartzG.F., HortobagyiG.N.Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania.Cancer2004; 100: 2512–32.
14.
GibsonG.R., LesnikoskiB.A., YooJ.A comparison of ink-directed and traditional whole-cavity re-excision for breast lumpectomy specimens with positive margins.Ann Surg Oncol2001; 8: 693–704.
15.
TaneiT., MorimotoK., ShimazuK.Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.Clin Cancer Res2009; 15: 4234–41.
16.
LanninD.R., GrubeB., BlackD.S., PonnT.Breast tattoos for planning surgery following neoadjuvant chemotherapy.Am J Surg2007; 194: 518–20.
17.
ChristyC.J., ThorsteinssonD., GrubeB.J.Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter.Ann Surg Oncol2009; 16: 697–702.
18.
ZavagnoG., GoldinE., MencarelliR.Role of resection margins in patients treated with breast conservation surgery.Cancer2008; 112: 1923–31.
19.
O'SullivanM.J., LiT., FreedmanG., MorrowM.The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery.Ann Surg Oncol2007; 14: 3133–40.
